Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03052400 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Charles Drew University of Medicine and Science.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03052400: Clinical Trial Phase 2 study, sponsored by Charles Drew University of Medicine and Science.
NCT03052400 is a Phase 2 study that was terminated before completion, run by Charles Drew University of Medicine and Science. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03052400, a Phase 2 study, was terminated before completion, sponsored by Charles Drew University of Medicine and Science.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated with Cushing's syndrome
Primary Outcome
Glycemic lowering
Interventions
- DRUG Placebo
- DRUG Mifepristone 600 mg daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-02-03 |
| Est. Completion | 2021-05-31 |
| Phase | Phase 2 |
Why NCT03052400 stopped before completion
NCT03052400 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03052400 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03052400 about?
NCT03052400 is a clinical study titled "Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus". Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated with Cushing's syndrome
What is the current status of trial NCT03052400?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2017-02-03. Estimated completion is 2021-05-31.
What interventions are being tested in trial NCT03052400?
The interventions under investigation include: Placebo (DRUG), Mifepristone 600 mg daily (DRUG).
Who is sponsoring clinical trial NCT03052400?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03052400's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI